NR1I3 and hepatocellular carcinoma: For instance, it has been linked to hepatomegaly and hepatocyte proliferation, which increases liver stress.[106] Another concern is that CAR activation may disrupt the balance of sex hormones and thyroid hormones, leading to endocrine issues.[107] Prolonged activation has also been associated with an increased risk of hepatocellular carcinoma.[108, 109] Notably, TCPOBOP has shown hepato‐protective effects, such as reducing liver injury.[110, 111] In our study, TCPOBOP reduced liver inflammation, suggesting it might affect an adaptive response rather than toxicity.